Bevacizumab plus chemotherapy for ovarian cancer

被引：0
|
作者：
Ozkan, Judy
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 06期
关键词：
D O I：
10.1016/S1470-2045(14)70142-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E202 / E202
页数：1
相关论文
共 50 条
  • [21] The efficacy and toxicity of bevacizumab plus genicitabine in patients with recurrent ovarian cancer
    Bevis, K. S.
    Numnum, T. M.
    Shipman, K. A.
    Makhija, S.
    Barnes, M. N.
    Straughn, J.
    GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S119 - S120
  • [22] Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer
    Chura, Justin C.
    Van Iseghem, Kelin
    Downs, Levi S., Jr.
    Carson, Linda F.
    Judson, Patricia L.
    GYNECOLOGIC ONCOLOGY, 2007, 107 (02) : 326 - 330
  • [23] LOCALIZED OVARIAN-CANCER - SURGERY PLUS CHEMOTHERAPY
    FIORENTINO, MV
    NICOLETTO, O
    DEBESI, P
    STEFANI, G
    TREDESE, F
    VINANTE, O
    FORNASIERO, A
    CECCHETTO, A
    MAGGINO, T
    MARCHESONI, D
    NARDELLI, G
    ONNIS, A
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1986, 22 (11): : 1365 - 1370
  • [24] Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
    Ray-Coquard, I.
    Pautier, P.
    Pignata, S.
    Perol, D.
    Gonzalez-Martin, A.
    Berger, R.
    Fujiwara, K.
    Vergote, I.
    Colombo, N.
    Maenpaa, J.
    Selle, F.
    Sehouli, J.
    Lorusso, D.
    Alia, E. M. Guerra
    Reinthaller, A.
    Nagao, S.
    Lefeuvre-Plesse, C.
    Canzler, U.
    Scambia, G.
    Lortholary, A.
    Marme, F.
    Combe, P.
    de Gregorio, N.
    Rodrigues, M.
    Buderath, P.
    Dubot, C.
    Burges, A.
    You, B.
    Pujade-Lauraine, E.
    Harter, P.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (25): : 2416 - 2428
  • [25] A meta-analysis of bevacizumab combined with chemotherapy in the treatment of ovarian cancer
    Wang, T. S.
    Lei, W.
    Cui, W.
    Wen, P.
    Guo, H. F.
    Ding, S. G.
    Yang, Y. P.
    Xu, Y. Q.
    Lv, S. W.
    Zhu, Y. L.
    INDIAN JOURNAL OF CANCER, 2014, 51 (07) : 95 - 98
  • [26] FOCUS STUDY: Physician's Choice Chemotherapy (PCC) Plus Bevacizumab and CA4P Versus PCC Plus Bevacizumab and Placebo in Platinum-Resistant Ovarian Cancer
    Monk, B. J.
    Herzog, T.
    Alvarez, R.
    Chan, J.
    Chase, D.
    Couchenour, R.
    Cram, C.
    Bookman, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 878 - 879
  • [27] Use of Bevacizumab in Combination with Chemotherapy in Ovarian Cancer in a Community Practice Setting
    Loh, K.
    HONG KONG JOURNAL OF RADIOLOGY, 2012, 15 (04): : S88 - S90
  • [28] Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer
    Cohn, David E.
    Valmadre, Sue
    Resnick, Kimberly E.
    Eaton, Lynne A.
    Copeland, Larry J.
    Fowler, Jeffrey M.
    GYNECOLOGIC ONCOLOGY, 2006, 102 (02) : 134 - 139
  • [29] Bevacizumab Plus Chemotherapy Cost Effectiveness
    Bordonaro, Roberto
    Cordio, Stefano
    Uccello, Mario
    Martines, Concetta
    Fassari, Giuseppina E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3840 - +
  • [30] BEVACIZUMAB AND PLATINUM-BASED CHEMOTHERAPY IN RELAPSED OVARIAN CANCER TREATMENT
    Davidenko, I.
    Kazantseva, M.
    Porhanova, N.
    Potemin, S.
    Oganyan, M.
    Syrota, L.
    Shmatkova, V.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
12345